$XTNT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in XTENT INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in XTENT INC. Get notifications about new insider transactions in XTENT INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 04 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 6.81 | 100 | 681 | 99,450 | 99.6 K to 99.5 K (-0.10 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.85 | 300 | 2,055 | 114,500 | 114.8 K to 114.5 K (-0.26 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.86 | 3,066 | 21,033 | 114,800 | 117.9 K to 114.8 K (-2.60 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.87 | 700 | 4,809 | 117,866 | 118.6 K to 117.9 K (-0.59 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.90 | 200 | 1,380 | 118,566 | 118.8 K to 118.6 K (-0.17 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.91 | 34 | 235 | 118,766 | 118.8 K to 118.8 K (-0.03 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.94 | 34 | 236 | 118,800 | 118.8 K to 118.8 K (-0.03 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.95 | 67 | 466 | 118,834 | 118.9 K to 118.8 K (-0.06 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 6.98 | 200 | 1,396 | 118,901 | 119.1 K to 118.9 K (-0.17 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 7.46 | 200 | 1,492 | 119,101 | 119.3 K to 119.1 K (-0.17 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 7.50 | 66 | 495 | 119,301 | 119.4 K to 119.3 K (-0.06 %) |
Mar 04 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 7.52 | 133 | 1,000 | 119,367 | 119.5 K to 119.4 K (-0.11 %) |
Feb 12 2008 | XTNT | XTENT INC | Campbell Randolph E | Chief Technical Off ... | Option Exercise | A | 9.96 | 3,628 | 36,135 | 3,628 | |
Feb 12 2008 | XTNT | XTENT INC | Campbell Randolph E | Chief Technical Off ... | Option Exercise | A | 9.96 | 23,447 | 233,532 | 23,447 | |
Feb 12 2008 | XTNT | XTENT INC | Hodkinson Anne-Marie | VP Human Resources | Option Exercise | A | 9.96 | 56,227 | 560,021 | 57,460 | |
Feb 12 2008 | XTNT | XTENT INC | Hodkinson Anne-Marie | VP Human Resources | Option Exercise | A | 9.96 | 1,233 | 12,281 | 1,233 | |
Feb 12 2008 | XTNT | XTENT INC | Hodkinson Anne-Marie | VP Human Resources | Option Exercise | A | 9.96 | 3,773 | 37,579 | 3,809 | |
Feb 12 2008 | XTNT | XTENT INC | Hodkinson Anne-Marie | VP Human Resources | Option Exercise | A | 9.96 | 36 | 359 | 36 | |
Feb 12 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 9.96 | 2,642 | 26,314 | 2,642 | |
Feb 12 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Option Exercise | A | 9.96 | 24,433 | 243,353 | 24,433 | |
Feb 12 2008 | XTNT | XTENT INC | Andreas Bernard H | VP-Research & Devel ... | Option Exercise | A | 9.96 | 14,575 | 145,167 | 14,575 | |
Feb 12 2008 | XTNT | XTENT INC | Casciaro Gregory D | President and CEO | Option Exercise | A | 9.96 | 56,170 | 559,453 | 56,170 | |
Feb 12 2008 | XTNT | XTENT INC | Casciaro Gregory D | President and CEO | Option Exercise | A | 9.96 | 25,055 | 249,548 | 25,055 | |
Feb 12 2008 | XTNT | XTENT INC | Kahlenberg Timothy D | Chief Financial Off ... | Option Exercise | A | 9.96 | 8,345 | 83,116 | 8,345 | |
Feb 12 2008 | XTNT | XTENT INC | Kahlenberg Timothy D | Chief Financial Off ... | Option Exercise | A | 9.96 | 24,980 | 248,801 | 24,980 | |
Feb 12 2008 | XTNT | XTENT INC | Walsh Brian J | VP-Sales & Marketin ... | Option Exercise | A | 9.96 | 2,745 | 27,340 | 2,745 | |
Feb 12 2008 | XTNT | XTENT INC | Walsh Brian J | VP-Sales & Marketin ... | Option Exercise | A | 9.96 | 24,330 | 242,327 | 24,330 | |
Feb 12 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Option Exercise | A | 9.96 | 2,577 | 25,667 | 2,577 | |
Feb 12 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Option Exercise | A | 9.96 | 24,498 | 244,000 | 24,498 | |
Feb 06 2008 | XTNT | XTENT INC | Casciaro Gregory D | President and CEO | Sell | S | 9.75 | 1,500 | 14,625 | 632,700 | 634.2 K to 632.7 K (-0.24 %) |
Feb 06 2008 | XTNT | XTENT INC | Casciaro Gregory D | President and CEO | Sell | S | 9.80 | 500 | 4,900 | 634,200 | 634.7 K to 634.2 K (-0.08 %) |
Feb 05 2008 | XTNT | XTENT INC | Grainger Jeffry J | VP-Corp Affairs & G ... | Sell | S | 9.55 | 5,000 | 47,750 | 119,500 | 124.5 K to 119.5 K (-4.02 %) |
Jan 28 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 3,500 | 35,077 | 103,050 | 106.6 K to 103.1 K (-3.28 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.83 | 100 | 983 | 99,550 | 99.7 K to 99.6 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.80 | 100 | 980 | 99,650 | 99.8 K to 99.7 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.79 | 100 | 979 | 99,750 | 99.9 K to 99.8 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 100 | 976 | 99,850 | 100 K to 99.9 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 100 | 976 | 99,950 | 100.1 K to 100 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.75 | 400 | 3,900 | 100,050 | 100.5 K to 100.1 K (-0.40 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.74 | 200 | 1,948 | 100,450 | 100.7 K to 100.5 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.74 | 200 | 1,948 | 100,650 | 100.9 K to 100.7 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.73 | 100 | 973 | 100,850 | 101 K to 100.9 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.72 | 100 | 972 | 100,950 | 101.1 K to 101 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.70 | 100 | 970 | 101,050 | 101.2 K to 101.1 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.69 | 100 | 969 | 101,150 | 101.3 K to 101.2 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.68 | 200 | 1,936 | 101,250 | 101.5 K to 101.3 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.65 | 500 | 4,825 | 101,450 | 102 K to 101.5 K (-0.49 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.53 | 200 | 1,906 | 101,950 | 102.2 K to 102 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.48 | 100 | 948 | 102,150 | 102.3 K to 102.2 K (-0.10 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.45 | 200 | 1,890 | 102,250 | 102.5 K to 102.3 K (-0.20 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.42 | 300 | 2,826 | 102,450 | 102.8 K to 102.5 K (-0.29 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.41 | 200 | 1,882 | 102,750 | 103 K to 102.8 K (-0.19 %) |
Feb 05 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.39 | 100 | 939 | 102,950 | 103.1 K to 103 K (-0.10 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.20 | 100 | 920 | 106,550 | 106.7 K to 106.6 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.14 | 125 | 1,143 | 106,650 | 106.8 K to 106.7 K (-0.12 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.13 | 200 | 1,826 | 106,775 | 107 K to 106.8 K (-0.19 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.12 | 475 | 4,332 | 106,975 | 107.5 K to 107 K (-0.44 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.11 | 100 | 911 | 107,450 | 107.6 K to 107.5 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.08 | 100 | 908 | 107,550 | 107.7 K to 107.6 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.07 | 100 | 907 | 107,650 | 107.8 K to 107.7 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.06 | 100 | 906 | 107,750 | 107.9 K to 107.8 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.05 | 100 | 905 | 107,850 | 108 K to 107.9 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.89 | 400 | 3,956 | 107,950 | 108.4 K to 108 K (-0.37 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.85 | 200 | 1,970 | 108,350 | 108.6 K to 108.4 K (-0.18 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.84 | 200 | 1,968 | 108,550 | 108.8 K to 108.6 K (-0.18 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.79 | 400 | 3,916 | 108,750 | 109.2 K to 108.8 K (-0.37 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 400 | 3,904 | 109,150 | 109.6 K to 109.2 K (-0.37 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.66 | 100 | 966 | 109,550 | 109.7 K to 109.6 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.63 | 100 | 963 | 109,650 | 109.8 K to 109.7 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.62 | 100 | 962 | 109,750 | 109.9 K to 109.8 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.61 | 100 | 961 | 109,850 | 110 K to 109.9 K (-0.09 %) |
Jan 03 2008 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.60 | 100 | 960 | 109,950 | 110.1 K to 110 K (-0.09 %) |
Dec 27 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.00 | 1,700 | 17,000 | 110,050 | 111.8 K to 110.1 K (-1.52 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.32 | 100 | 932 | 111,750 | 111.9 K to 111.8 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.29 | 100 | 929 | 111,850 | 112 K to 111.9 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.23 | 100 | 923 | 111,950 | 112.1 K to 112 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.22 | 100 | 922 | 112,050 | 112.2 K to 112.1 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.20 | 200 | 1,840 | 112,150 | 112.4 K to 112.2 K (-0.18 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.19 | 100 | 919 | 112,350 | 112.5 K to 112.4 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.18 | 100 | 918 | 112,450 | 112.6 K to 112.5 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.17 | 100 | 917 | 112,550 | 112.7 K to 112.6 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.14 | 200 | 1,828 | 112,650 | 112.9 K to 112.7 K (-0.18 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.12 | 100 | 912 | 112,850 | 113 K to 112.9 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.10 | 1,000 | 9,100 | 112,950 | 114 K to 113 K (-0.88 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.07 | 100 | 907 | 113,950 | 114.1 K to 114 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.05 | 100 | 905 | 114,050 | 114.2 K to 114.1 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.04 | 300 | 2,712 | 114,150 | 114.5 K to 114.2 K (-0.26 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.02 | 100 | 902 | 114,450 | 114.6 K to 114.5 K (-0.09 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.01 | 300 | 2,703 | 114,550 | 114.9 K to 114.6 K (-0.26 %) |
Dec 07 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.00 | 400 | 3,600 | 114,850 | 115.3 K to 114.9 K (-0.35 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.22 | 100 | 1,022 | 114,000 | 114.1 K to 114 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.17 | 100 | 1,017 | 114,100 | 114.2 K to 114.1 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.13 | 100 | 1,013 | 114,200 | 114.3 K to 114.2 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.11 | 100 | 1,011 | 114,300 | 114.4 K to 114.3 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.10 | 100 | 1,010 | 114,400 | 114.5 K to 114.4 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.06 | 200 | 2,012 | 114,500 | 114.7 K to 114.5 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.03 | 100 | 1,003 | 114,700 | 114.8 K to 114.7 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 100 | 1,002 | 114,800 | 114.9 K to 114.8 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 100 | 1,002 | 114,900 | 115 K to 114.9 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.96 | 100 | 996 | 115,000 | 115.1 K to 115 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.95 | 200 | 1,990 | 115,100 | 115.3 K to 115.1 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.94 | 100 | 994 | 115,300 | 115.4 K to 115.3 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.90 | 1,000 | 9,900 | 115,400 | 116.4 K to 115.4 K (-0.86 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.89 | 200 | 1,978 | 116,400 | 116.6 K to 116.4 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.87 | 100 | 987 | 116,600 | 116.7 K to 116.6 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.86 | 300 | 2,958 | 116,700 | 117 K to 116.7 K (-0.26 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.85 | 100 | 985 | 117,000 | 117.1 K to 117 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.82 | 200 | 1,964 | 117,100 | 117.3 K to 117.1 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.79 | 100 | 979 | 117,300 | 117.4 K to 117.3 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 9.76 | 100 | 976 | 117,400 | 117.5 K to 117.4 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.17 | 100 | 1,017 | 117,500 | 117.6 K to 117.5 K (-0.09 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.16 | 100 | 1,016 | 117,600 | 117.7 K to 117.6 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.15 | 100 | 1,015 | 117,700 | 117.8 K to 117.7 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.11 | 100 | 1,011 | 117,800 | 117.9 K to 117.8 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.10 | 100 | 1,010 | 117,900 | 118 K to 117.9 K (-0.08 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.07 | 200 | 2,014 | 118,000 | 118.2 K to 118 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.02 | 200 | 2,004 | 118,200 | 118.4 K to 118.2 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.01 | 200 | 2,002 | 118,400 | 118.6 K to 118.4 K (-0.17 %) |
Nov 01 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.00 | 2,400 | 24,000 | 118,600 | 121 K to 118.6 K (-1.98 %) |
Oct 18 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 10.01 | 3,500 | 35,035 | 121,000 | 124.5 K to 121 K (-2.81 %) |
Oct 02 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.51 | 200 | 1,702 | 124,500 | 124.7 K to 124.5 K (-0.16 %) |
Oct 02 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.50 | 3,300 | 28,050 | 124,700 | 128 K to 124.7 K (-2.58 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.94 | 300 | 2,382 | 128,000 | 128.3 K to 128 K (-0.23 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.09 | 300 | 2,427 | 128,300 | 128.6 K to 128.3 K (-0.23 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.08 | 100 | 808 | 128,600 | 128.7 K to 128.6 K (-0.08 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.03 | 100 | 803 | 128,700 | 128.8 K to 128.7 K (-0.08 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.02 | 200 | 1,604 | 128,800 | 129 K to 128.8 K (-0.16 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 8.00 | 100 | 800 | 129,000 | 129.1 K to 129 K (-0.08 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.98 | 400 | 3,192 | 129,100 | 129.5 K to 129.1 K (-0.31 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.97 | 400 | 3,188 | 129,500 | 129.9 K to 129.5 K (-0.31 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.96 | 100 | 796 | 129,900 | 130 K to 129.9 K (-0.08 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.95 | 500 | 3,975 | 130,000 | 130.5 K to 130 K (-0.38 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.93 | 300 | 2,379 | 130,500 | 130.8 K to 130.5 K (-0.23 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.92 | 300 | 2,376 | 130,800 | 131.1 K to 130.8 K (-0.23 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.91 | 200 | 1,582 | 131,100 | 131.3 K to 131.1 K (-0.15 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.81 | 100 | 781 | 131,300 | 131.4 K to 131.3 K (-0.08 %) |
Sep 05 2007 | XTNT | XTENT INC | Marco Philippe H | VP-QA, Clinical & R ... | Sell | S | 7.78 | 100 | 778 | 131,400 | 131.5 K to 131.4 K (-0.08 %) |
Aug 13 2007 | XTNT | XTENT INC | EAGLE MICHAEL L | Director | Option Exercise | A | 9.06 | 30,000 | 271,800 | 30,000 | |
Jun 22 2007 | XTNT | XTENT INC | Unkart Edward W | Director | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
Jun 22 2007 | XTNT | XTENT INC | Split Rock Partners LLC | 10% Owner | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
Jun 22 2007 | XTNT | XTENT INC | Plain Henry A JR | Director | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
Jun 22 2007 | XTNT | XTENT INC | Will Allan R | Director | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
Jun 22 2007 | XTNT | XTENT INC | Bellas Robert C JR | Director | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
Jun 22 2007 | XTNT | XTENT INC | FLAHERTY ROBERT E | Director | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
Jun 22 2007 | XTNT | XTENT INC | Carusi Michael A | Director | Option Exercise | A | 8.94 | 10,000 | 89,400 | 10,000 | |
May 11 2007 | XTNT | XTENT INC | TRAVELERS COMPANIES, INC. | 10% Owner | Sell | J | 0.00 | 2,615,135 | 0 | 0 | 2.6 M to 0 (-100.00 %) |
Feb 07 2007 | XTNT | XTENT INC | Will Allan R | Director | Option Exercise | C | 0.00 | 337,078 | 0 | 0 | |
Feb 07 2007 | XTNT | XTENT INC | Will Allan R | Director | Option Exercise | C | 0.00 | 1,014,760 | 0 | 0 | |
Feb 07 2007 | XTNT | XTENT INC | Will Allan R | Director | Option Exercise | C | 0.00 | 1,263,297 | 0 | 0 | |
Feb 07 2007 | XTNT | XTENT INC | Will Allan R | Director | Buy | C | 0.00 | 2,615,135 | 0 | 2,615,135 | 0 to 2.6 M |